Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials


In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.


Currently viewing trials
(Last updated: September 27, 2020)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2 (inherited)

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

Close

AKT

ALK

AR

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

RB

ROS1

TP53

1

NEAREST SITE: 8 miles
Epic Care Partners in Cancer Care
Emeryville,CA

VISITS: 5 visits per week, for 6 weeks

PHASE: II

NCT ID: NCT03598257

Radiation Therapy With or Without Olaparib For Inflammatory Breast Cancer

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer (SWOG 1706) Scientific Title

Purpose
To compare the benefits and the effects (good and bad) of using radiation therapy along with a PARP inhibitor to radiation therapy alone.
Who is this for?
People with stage III inflammatory breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily, for 6 weeks</li> <li class="seamTextUnorderedListItem">Radiation therapy, 5 days a week, for 6 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy, 5 days a week, for 6 weeks</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The PARP inhibitor being used in this study is olaparib (Lynparza®). It is approved to treat HER2-negative metastatic breast cancer in women with an inherited BRCA1/2 mutation. </li> <li class="seamTextUnorderedListItem">PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA. </li> <li class="seamTextUnorderedListItem">Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03598257' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2018/fda-olaparib-breast-brca-mutations' target='_blank'>NCI: Olaparib Approved for Treating Some Breast Cancers with BRCA Gene Mutations</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/drugs/olaparib' target='_blank'>NCI: Olaparib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/types/inflammatory' target='_blank'>Breastcancer.org: Inflammatory Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.swog.org/clinical-trials/s1706' target='_blank'>SWOG Cancer Research Network: Trial information</a> </li></ul>
See more
2

NEAREST SITE: 1615 miles
Mayo Clinic
Rochester,MN

VISITS: 2-4 visits per month for 7 months

PHASE: II

NCT ID: NCT02876302

Ruxolitinib and Chemo Before Surgery for Stage III or Stage IV Triple Negative Inflammatory Breast Cancer

Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer Scientific Title

Purpose
To study the safety and effects (good and bad) of using a new targeted therapy in combination with chemotherapy.
Who is this for?
People with stage III or stage IV (metastatic) triple negative (ER-, PR-, HER2-), inflammatory breast cancer    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups and receive the following before surgery: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, for 3 months </li> <li class="seamTextUnorderedListItem">followed by AC chemotherapy, by IV, every 2 weeks, for 4 months </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, for 3 months </li> <li class="seamTextUnorderedListItem">Ruxolitinib (Jakafi®), by mouth, daily, for 3 months </li> <li class="seamTextUnorderedListItem">followed by AC chemotherapy, by IV, every 2 weeks, for 4 months </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, for 3 months </li> <li class="seamTextUnorderedListItem">Ruxolitinib (Jakafi®), by mouth, daily, for 3 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The targeted therapy being used in this trial is ruxolitinib (Jakafi®). It is used to treat myelofibrosis, a disease of the bone marrow.</li> <li class="seamTextUnorderedListItem">Laboratory studies suggest Jakafi may make chemotherapy more effective.</li> <li class="seamTextUnorderedListItem">The chemotherapy drugs that will be used in this study are paclitaxel (Taxol®), doxorubicin (Adriamycin®) and cyclophosophamide (Cytoxan®).</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02876302' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/jakafi' target='_blank'>NCI Drug Dictionary: Jakafi</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.theibcnetwork.org' target='_blank'>The IBC Network Foundation</a> </li></ul>
See more
3

NEAREST SITE: 1621 miles
MD Anderson in The Woodlands
The Woodlands,TX

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT00477100

Inflammatory Breast Cancer Registry

Inflammatory Breast Cancer (IBC) Registry Scientific Title

Purpose
To collect blood and tissue samples and clinical data.
Who is this for?
People with new clinical diagnosis of primary inflammatory breast cancer (IBC), second primary IBC, or highly suspicious for IBC.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> All participants will have the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Additional blood drawn during a routine blood draw</li> <li class="seamTextUnorderedListItem">Core, breast tissue, and skin biopsy (performed for diagnosis)</li> <li class="seamTextUnorderedListItem">Medical history interview</li> <li class="seamTextUnorderedListItem">Clinical data collected from your medical records</li> <li class="seamTextUnorderedListItem">Photographs of both breasts</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"><span class="highlight">Inflammatory</span> breast cancer is a rare, aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin, causing the breast to appear red and swollen. </li> <li class="seamTextUnorderedListItem">Researchers have not yet identified any genes or other risk factors that they could use to design better treatments for <span class="highlight">inflammatory</span> breast cancer.</li> </ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00477100' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/cancertopics/factsheet/sites-types/ibc' target='_blank'>Cancer.gov: Inflammatory Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/symptoms/types/inflammatory' target='_blank'>BreastCancer.org: IBC</a> </li><li class='seamTextUnorderedListItem'><a href='http://scholar.google.com/scholar?q=inflammatory+breast+cancer&hl=en&btnG=Search' target='_blank'>Google Scholar: IBC</a> </li></ul>
See more
4

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Weekly visits

PHASE: I-II

NCT ID: NCT03101748

Adding Neratinib to Treatment Regimens for Advanced or Inflammatory Breast Cancer

A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC Scientific Title

Purpose
To investigate the safety and best dose of neratinib (Nerlynx®) to add to drug regimens used to treat advanced breast cancer.
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) breast cancer that is HER2-positive. If you have inflammatory breast cancer, your tumor can be either HER2 positive (HER2+) or HER2 negative (HER2-) so long as its also estrogen receptor positive (ER+).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: HER2 Positive</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, monthly</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, monthly</li> <li class="seamTextUnorderedListItem">Keep a medication diary about neratinib</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: HER2 Positive <span class="highlight">Inflammatory</i></span> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, monthly</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, monthly</li> <li class="seamTextUnorderedListItem">Doxorubicin and cyclophosphamide, by IV, monthly</li> <li class="seamTextUnorderedListItem">followed by surgery</li> <li class="seamTextUnorderedListItem">Keep a medication diary about neratinib</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: HER2 Negative/ER Positive <span class="highlight">Inflammatory</i></span> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly</li> <li class="seamTextUnorderedListItem">Doxorubicin and cyclophosphamide, by IV, monthly</li> <li class="seamTextUnorderedListItem">followed by surgery</li> <li class="seamTextUnorderedListItem">Keep a medication diary about neratinib</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®) is a tyrosine kinase inhibitor approved for use in patients with HER2 positive (HER2+) breast cancer</li> <li class="seamTextUnorderedListItem">The HER2-targeted drugs used in this study are pertuzumab (Perjeta®) and Herceptin. </li> <li class="seamTextUnorderedListItem">The chemotherapy drugs used in this study are doxorubicin/Adriamicin® and cyclophosphamide/Cytoxan®. </li> <li class="seamTextUnorderedListItem">Your treatment regimen will be determined by whether your tumor is HER2+ or HER2- and if you have <span class="highlight">inflammatory</span> breast cancer. </li> <li class="seamTextUnorderedListItem">Women with <span class="highlight">inflammatory</span> breast cancer will also have surgery.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03101748' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.onclive.com/inside-oncology/adam-brufsky-md/neratinib-for-metastatic-breast-cancer' target='_blank'>OncLive: Neratinib for Metastatic Breast Cancer (Video)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/web-exclusives/neratinib-improves-pfs-in-her2-metastatic-breast-cancer' target='_blank'>OncLive: Neratinib Improves PFS in HER2+ MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancer-news.com/pb272-neratinib/' target='_blank'>Breast Cancer News: Neratinib</a> </li></ul>
See more
5

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Visits once every 3 weeks, ongoing

PHASE: II

NCT ID: NCT02971748

Keytruda + an Anti-Estrogen Drug for HR+ Inflammatory Breast Cancer

A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Hormonal Therapy in Patients With Hormone Receptor (HR)-Positive Localized Inflammatory Breast Cancer (IBC) Who Did Not Achieve a Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy Scientific Title

Purpose
To study the effects (good and bad) of treating inflammatory breast cancer with an immunotherapy drug along with a standard anti-estrogen drug.
Who is this for?
People with hormone receptor positive (ER+ and/or PR+) inflammatory breast cancer. You must have received chemotherapy prior to breast surgery, but tumor cells were still present after therapy was completed.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following for up to 2 years: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, once every 3 weeks</li> <li class="seamTextUnorderedListItem">Physician's choice hormone therapy (tamoxifen/Nolvadex®, exemestane/Aromasin®, anastorzole/Arimidex®, letrozole/Femara®, LHRH agonist), by mouth, daily</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The immunotherapy drug (treatment that uses your body's own immune system to help fight cancer) being used in this study is pembrolizumab (Keytruda®). </li> <li class="seamTextUnorderedListItem">Your doctor will choose which anti-estrogen drug you receive: tamoxifen/Nolvadex®, exemestane/Aromasin®, anastrozole/Arimidex®, or letrozole/Femara®. </li> <li class="seamTextUnorderedListItem">If you are premenopausal, you may also receive a therapy that will stop your ovaries from producing estrogen. </li> </ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02971748' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/cancer-types/inflammatory-breast-cancer.html' target='_blank'>MD Anderson Inflammatory Breast Cancer Clinic</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/symptoms/types/inflammatory' target='_blank'>Inflammatory Breast Cancer</a> </li></ul>
See more
6

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 visit every 3 weeks, ongoing

PHASE: II

NCT ID: NCT02411656

Pembrolizumab for Metastatic HER2- Inflammatory, Triple Negative, and ER-Low Breast Cancer

A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer Who Have Received Prior Chemotherapy With Clinical Response Scientific Title

Purpose
To look at the safety and effects (good and bad) of using pembrolizumab (Keytruda®).
Who is this for?
People with metastatic (stage IV) HER2 negative inflammatory, triple negative (ER-, PR-, HER2-), or ER-Low (1%-10%) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with triple negative as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is an immunotherapy that helps the body's immune system slow or stop cancer cell growth by blocking a protein known as programmed cell death receptor-1 (PD-1).</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02411656' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/?src=google&med=cpc&camp=Keytruda+Pan+Tumor_Brand_BRND_NA_ENGM_EXCT_TEXT_NA&adgrp=Brand+Keyword_General&kw=keytruda&utm_kxconfid=sq7irm3mh&gclid=CjwKCAjwy7vlBRACEiwAZvdx9jIPFQgWidLA-C5wT1MzjtITa1lJzO4axMQhgd1rro0RP5g40-abvxoCQlYQA' target='_blank'>Merck Drug Information Page: Keytruda</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pembrolizumab' target='_blank'>NCI Drug Dictionary: Pembrolizumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/Inflammatory-Breast-Cancer.html' target='_blank'>Susan G. Komen: Inflammatory Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/TripleNegativeBreastCancer.html' target='_blank'>Susan G. Komen: Triple Negative Breast Cancer</a> </li></ul>
See more
7

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 visit every week to 2 weeks, ongoing

PHASE: II

NCT ID: NCT03202316

Tecentriq, Cotellic & Halaven for Metastatic Inflammatory Breast Cancer

A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer Scientific Title

Purpose
To determine the safety and effects (good and bad) of a combination therapy including chemotherapy, immunotherapy, and targeted therapies.
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) inflammatory breast cancer. If your cancer is HER2 positive (HER2+), you must have received at least two anti-HER2 therapies, including pertuzumab (Perjeta®) and T-DM1 (Kadcyla®).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">First 2 weeks</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, once</li> <li class="seamTextUnorderedListItem">Cobimetinib (Cotellic®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Eribulin (Halaven®), by IV, 8 times over 3.5 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Followed by</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 2 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Cobimetinib (Cotellic®), mouth, weekly (3 weeks on, 1 week off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-L1 inhibitor. </li> <li class="seamTextUnorderedListItem">FDA has approved Tecentriq® to treat certain types of bladder and lung cancer. </li> <li class="seamTextUnorderedListItem">Cobimetinib (Cotellic®) is a new targeted therapy called an MEK inhibitor. It is approved to treat certain types of melanoma. </li> <li class="seamTextUnorderedListItem">Eribulin (Halaven®) is a chemotherapy drug approved for treating metastatic breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03202316' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tecentriq.com' target='_blank'>Genentech Information Page: Tecentriq</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Cobimetinib' target='_blank'>Wikipedia: Cobimetinib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cotellic.com' target='_blank'>Genentech Information Page: Cotellic</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.halaven.com/metastatic-breast-cancer' target='_blank'>Drug Company Information Page: Halaven</a> </li></ul>
See more
8

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Visits every 1-3 weeks over 6 months

PHASE: II

NCT ID: NCT02876107

Vectibix and Chemotherapy Before Surgery for Triple Negative Inflammatory Breast Cancer

A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer Scientific Title

Purpose
To see if chemotherapy combinations used to treat advanced breast cancer are more effective when given along with a targeted drug. The treatments are given before you have surgery.
Who is this for?
Women who are newly diagnosed with stage III, inflammatory triple negative (ER-, PR-, HER2-) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups and will receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Chemo with Vectibix for 3 months</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Panitumumab (Vectibix®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Chemo without Vectibix for 3 months</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Followed by:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AC (Adriamycin® and Cytoxan®), by IV, every 3 weeks, for 3 months</li> <li class="seamTextUnorderedListItem">followed by surgery</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The initial chemotherapy combination is carboplatin (Paraplatin®) and paclitaxel (Taxol®). </li> <li class="seamTextUnorderedListItem">It is followed by doxorubicin (Adriamycin®) and cyclophosphamide (Cytoxan®)--known as AC. </li> <li class="seamTextUnorderedListItem">The targeted drug is panitumumab (Vectibix®).</li> <li class="seamTextUnorderedListItem">Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells only, doing less harm to normal cells. </li> <li class="seamTextUnorderedListItem">Vectibix® is currently used to treat a certain type of metastatic colorectal cancer. </li> <li class="seamTextUnorderedListItem">It is not yet known if Vectibix® will be effective as a treatment for breast cancer.</li> </ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02876107' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
9

NEAREST SITE: 1946 miles
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis,IN

VISITS: 3 to 8 visits a month, ongoing

PHASE: II

NCT ID: NCT04215146

Pelareorep with Taxol or with Taxol & Avelumab for Advanced HR+, HER2- Breast Cancer

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study Scientific Title

Purpose
To study the safety and anti-cancer activity of the experimental immunotherapy pelareorep when it is given in combination with paclitaxel (Taxol®) or with paclitaxel (Taxol®) and the PD-L1 inhibitor avelumab (Bavencio®).
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer whose disease progressed after they received a CDK 4/6 inhibitor in combination with hormone therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off), ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Pelareorep, by IV, 2 days a week (3 weeks on, 1 week off), ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Pelareorep, by IV, 2 days a week (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Avelumab (Bavencio®), by IV, every 2 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy used for advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Avelumab (Bevancio®) is an immunotherapy that works by stimulating the body's immune system to go after cancer cells by blocking a protein called PD-L1.</li> <li class="seamTextUnorderedListItem">Pelareorep is an oncolytic virus--this means it targets and kills cancer cells. It may directly kill cancer cells and stimulate your immune system to go after and kill cancer cells.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04215146' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Pelareorep' target='_blank'>Wikipedia: Pelareorep</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Avelumab' target='_blank'>Wikipedia: Avelumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/chemotherapy/paclitaxel-taxol' target='_blank'>Breast Cancer Now: Paclitaxel</a> </li></ul>
See more
10

NEAREST SITE: 2108 miles
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Wexner Medical Center
Columbus,OH

VISITS: At least 2 visits

PHASE: NA

NCT ID: NCT02415387

Typhoid Vaccine to Study Immune Response in Patients Who Received Chemotherapy

The IMPACT Study: Inflammatory Responses, Mood and Physical Fitness After Cancer Treatment Scientific Title

Purpose
To investigate how women who have completed treatment for early-stage breast cancer respond to a typhoid vaccine by measuring their cardiorespiratory fitness, natural inflammatory reaction, and behavioral responses such as depression, fatigue, pain, and problems with thinking and reasoning.
Who is this for?
Women who are postmenopausal and have received chemotherapy as part of breast cancer treatment.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> Participants will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Typhoid vaccine, by injection, on first visit</li> <li class="seamTextUnorderedListItem">followed by placebo, by injection, on second visit (2 weeks to 1 month later)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by injection, on first visit</li> <li class="seamTextUnorderedListItem">followed by typhoid vaccine, by injection, on second visit (2 weeks to 1 month later)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy can weaken the body's immune system. </li> <li class="seamTextUnorderedListItem">Physical fitness may protect the body from the effects that chemotherapy has on the immune system as well as reduce other health problems. </li> <li class="seamTextUnorderedListItem">Giving patients a typhoid vaccine allows researchers to study their immune response.</li> </ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02415387' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
11

NEAREST SITE: 2567 miles
Mount Sinai Beth Israel
New York,NY

VISITS: Number of visits varies, over 5 months before surgery, then 1 visit every 3 weeks for 9 months

PHASE: II

NCT ID: NCT03329378

Dose Dense Chemotherapy Before Surgery For Stage II-III HER2 Positive Breast Cancer

A Phase II Randomized Trial Evaluating Neoadjuvant Dose-Dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab/Pertuzumab (AC THP) and Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) For Early Her2Neu Positive Breast Cancer Scientific Title

Purpose
To compare the anti-cancer activity and side-effects of dose-dense chemotherapy to standard of care chemotherapy given before surgery.
Who is this for?
Women with stage II, stage IIIA or stage IIIB/C (locally advanced) HER2 positive (HER2+) or inflammatory breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups and receive the following before surgery: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Dose-dense chemotherapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AC (Doxorubicin (Adriamycin®) and Cyclophosphamide (Cytoxan®), by IV, every 2 weeks, for 2 months</li> <li class="seamTextUnorderedListItem">Pegfilgrastim (Neulasta®), by injection, every 2 weeks, for 2 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">followed by:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, once a week, for 3 months</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, once every 3 weeks, for 3 months</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, once every 3 weeks, to continue after surgery, for 1 year total</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard chemotherapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TCHP (Taxotere®, Carboplatin, Herceptin®, Perjeta®), by IV, once every 3 weeks, for 5 months</li> <li class="seamTextUnorderedListItem">Pegfilgrastim (Neulasta®), by injection, once every 3 weeks, for 5 months</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, please contact research site for the treatment schedule</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, once every 3 weeks, to continue after surgery, for 1 year total</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">One regimen will include doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab. </li> <li class="seamTextUnorderedListItem">The other will include docetaxel, carboplatin, trastuzumab, and pertuzumab.</li> <li class="seamTextUnorderedListItem">Doxorubicin (Adriamycin®), cyclophosphamide (Cytoxan®), docetaxel (Taxotere®), paclitaxel (Taxol® ), and carboplatin (Paraplatin®) are chemotherapy drugs used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) and Pertuzumab (Perjeta®) are HER2 targeted therapies used to treat HER2+ breast cancer. </li> <li class="seamTextUnorderedListItem">Pegfilgrastim (Neulasta®) is a drug that can stimulate the body to produce more white blood cells. It is routinely used to reduce the risk of infection in patients receiving chemotherapy.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03329378' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/breast-cancer/treatment/chemotherapy-for-breast-cancer.html' target='_blank'>American Cancer Society: Dose-dense chemotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy/process/when' target='_blank'>Breastcancer.org: Dose-dense chemotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2018-03595&r=1' target='_blank'>Cancer.gov: Trial summary</a> </li></ul>
See more
12

NEAREST SITE: 2568 miles
NYU Langone Health
New York,NY

VISITS: 1-2 visits a week for 5-6 months, before surgery

PHASE: II

NCT ID: NCT03742986

Immunotherapy Nivolumab & Chemotherapy Before Surgery for Inflammatory Breast Cancer

Phase II Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) Scientific Title

Purpose
To look at the effect of adding the immunotherapy drug nivolumab (Opdivo®) to chemotherapy routinely used before surgery (neoadjuvant treatment).
Who is this for?
People with newly diagnosed inflammatory breast cancer who have not yet started treatment.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups depending on the HER2 status of your tumor, and will receive the following treatment before surgery: </p> <p class="seamTextPara"> <i class="seamTextEmphasis"><u>Group 1: HER2 Negative</u></i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), by IV, every 3 weeks, for 3 months</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, every week, for 3 months</li> </ul> <p class="seamTextPara"> Then you will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Doxorubicin (Doxil®), by IV, every 2 weeks, for 2 months</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), by IV, every 2 weeks, for 2 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis"><u>Group 2: HER2 Positive</u></i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), by IV, every 3 weeks, for 3 months</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, every week, for 3 months OR Docetaxel (Taxotere®) every 3 weeks, for 3 months</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks, for 3 months</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, every 3 weeks, for 3 months</li> </ul> <p class="seamTextPara"> Then you will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Doxorubicin (Doxil®), by IV, every 2 weeks, for 2 months</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), by IV, every 2 weeks, for 2 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®) is a type of immunotherapy called a PD-1 inhibitor. </li> <li class="seamTextUnorderedListItem">It gets the immune system to go after cancer cells by blocking a protein called PD-1 (programmed cell death 1). </li> <li class="seamTextUnorderedListItem">It is approved to treat certain types of cancer. </li> <li class="seamTextUnorderedListItem">Its use in breast cancer is considered experimental.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03742986' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy' target='_blank'>Breastcancer.org: Immunotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.opdivo.com/' target='_blank'>Bristol-Meyers Squibb Information Page: Opdivo® (Nivolumab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/breast-cancer/treatment/chemotherapy-for-breast-cancer.html' target='_blank'>American Cancer Society: Chemotherapy for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/conference-coverage/sabcs-2018/association-between-pcr-and-neoadjuvant-chemo-shows-improved-breast-cancer-outcomes' target='_blank'>OncLive: Association Between pCR and Neoadjuvant Chemo Shows Improved Breast Cancer Outcomes</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.theibcnetwork.org/' target='_blank'>The IBC Network Foundation: What is Inflammatory Breast Cancer?</a> </li></ul>
See more
13

NEAREST SITE: 2693 miles
Dana-Farber Cancer Institute
Boston,MA

VISITS: At least 8 visits over 6 months plus surgery

PHASE: II

NCT ID: NCT02623972

Eribulin and AC Before Surgery for HER2-Negative Inflammatory Breast Cancer

A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Scientific Title

Purpose
To evaluate the safety and effects (good and bad) of treating HER2-negative inflammatory breast cancer with Halaven and AC before surgery.
Who is this for?
People with stage IIIb or IIIc HER2 negative inflammatory breast cancer. You must not have had surgery for your cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> All participants will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Eribulin (Halaven®) by IV, for 4 cycles</li> <li class="seamTextUnorderedListItem">followed by AC by IV, for 4 cycles</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">followed by surgery</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Eribulin (Halaven®) is a chemotherapy drug used to treat advanced breast cancer. </li> <li class="seamTextUnorderedListItem">AC (Adriamycin® and Cytoxan®) is used to treat <span class="highlight">inflammatory</span> breast cancer before surgery. </li> <li class="seamTextUnorderedListItem">Adding Halaven to the AC treatment may be more effective than using AC alone.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02623972' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.gov/ct2/show/NCT02623972' target='_blank'>ClinicalTrials.gov trial info</a> </li></ul>
See more